FoldRx Pharmaceuticals, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc. Announce $22 Million Collaboration

CAMBRIDGE, Mass. & BETHESDA, Md.--(BUSINESS WIRE)--FoldRx Pharmaceuticals, Inc. (FoldRx) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today that FoldRx will receive up to $22 million over five years to discover and develop new compounds aimed at treating a core defect in cystic fibrosis. The research, development and commercialization agreement — one of the largest of its kind for CFFT — calls for FoldRx to use its novel yeast-based, high throughput screening platform to detect new compounds that could improve the function of a misfolded protein associated with cystic fibrosis, thus helping treat the disease.

Back to news